Physician profile
John P Myers
NPI 1881661585
$152,046.67
in general payments reported to CMS, 2019-2025
18 companies · $18K in 2025
The $18K reported for 2025 was more than what 94% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22K · 2020: $16K · 2021: $19K · 2022: $27K · 2023: $33K · 2024: $17K · 2025: $18K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Travel and Lodging: $5,147 · Food and Beverage: $3,796.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $58,674.51 |
| Travel and Lodging | $5,146.73 |
| Food and Beverage | $3,795.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $103,264.26 | 2019-2025 | Eylea Hd, Eylea |
| US Retina LLC | $26,655.51 | 2019-2022 | |
| Genentech USA, INC. | $18,909.80 | 2019-2025 | Vabysmo |
| Apellis Pharmaceuticals, INC. | $911.82 | 2022-2025 | Syfovre |
| Allergan, INC. | $466.04 | 2019-2021 | |
| Alimera Sciences, INC. | $425.46 | 2019-2024 | Iluvien, Yutiq |
| Alcon Vision LLC | $414.24 | 2019-2024 | Constellation |
| Abbvie INC. | $214.14 | 2022-2024 | |
| Astellas Pharma US INC | $150.35 | 2025 | Izervay |
| Eyepoint US, INC. | $124.32 | 2022 | |
| Novartis Pharmaceuticals Corporation | $119.58 | 2019-2020 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $99.97 | 2019 | |
| Coopervision INC. | $92.15 | 2025 | Biofinity Contact Lens |
| Dompe US, INC. | $75.00 | 2024 | Oxervate |
| Bausch & Lomb Americas INC. | $42.12 | 2023-2024 | Xipere |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $37.83 | 2025 | Iluvien, Yutiq |
| Amgen INC. | $22.76 | 2025 | Tepezza |
| Biogen, INC. | $21.32 | 2024 | Byooviz |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$785,725.66 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Myers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.